Archive for December, 2008

Internal Medicine News - Sibutramine metaanalysis

Friday, December 26th, 2008

Sibutramine use was significantly associated with weight loss and appears to improve glycemic control and lipid profile in type 2 diabetics, reported Roberto Vettor, M.D., of the University of Padova, Italy, and his colleagues.
In a metaanalysis of eight placebo-controlled, double-blind trials, 552 obese patients with type 2 diabetes were randomized to sibutramine treatment, and 541 were randomiz…

Internal Medicine News - Sibutramine helps weight, lipids in obese adolescents: not yet approved for patients under age 16

Wednesday, December 24th, 2008

LAS VEGAS — Sibutramine (Meridia) enabled obese adolescents to shed weight and improve obesity-related risk factors in a 12-month, randomized, double-blind, placebo-controlled trial.
The proportion of teenagers who lost at least 5% of their body mass index (BMI) was more than three times greater in the sibutramine group compared with the control group–62% vs. 18%. Robert I. Berkowitz, M.D., reported at the annual meeting of North American Associatio…

Cheapest Meridia Reductil 10mg pills information

Saturday, December 20th, 2008

Meridia Pills (SIBUTRAMINE HCI) is a prescription medication thats used to help people lose unwanted weight by acting on the appetite control centers in the brain. Studies have shown that using Meridia Pills helps patients lose weight and maintain weight loss for up to 2 years. Before using Meridia Pills, tell…

Obesity drug Acomplia,Xenical,Reductil for Weight Loss.

Monday, December 15th, 2008

Obesity
Do you know which health risk is the second leading cause of deaths and illnesses? You guessed it right, after smoking, obesity is the most preventable health risk faced by the human race today.

Obesity doubles the chances of premature death
Diabetes, heart disease, high blood cholest…

Title: Some Treatments for Obesity

Saturday, December 13th, 2008

Obesity is fundamentally associated with increased morbidity and mortality. Weight loss reduces the risk factors for complications associated with the excess weight, including diabetes and cardiovascular diseases.There are other several treatment options for the management of ov…

Nutrition Research Newsletter - Leisure-time activity—important for long-term weight maintenance - Weight Management

Thursday, December 11th, 2008

DENVER — Weight-loss medications arguably should never be prescribed without also enrolling patients in some sort of behavioral modification program as well as a dietary intervention, Dr. Samuel Klein said at an international conference of the Academy for Eating Disorders.
This triple-pronged approach is essential. Studies clearly show that the long-term weight loss achieved with orlistat or sibutramine alone–the only two drugs approved for long-term t…

Reductil Slimming Pills

Monday, December 8th, 2008

Reductil slimming pills - these seem to have been in the news virtually every day recently. They have been hailed the ‘breakthrough in weight loss treatment’. But can a slimming pill actually work, or is the only way to lose weight and have a healthier lifestyle through exercise and a well balanced diet? Let’s take a closer look:

News: OSI Pharmaceuticals Initiates Clinical Development Program …

Sunday, December 7th, 2008

OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that it
has initiated the first-in-human clinical study of its development
compound PSN602. Discovered by OSI’s diabetes and obesity team, PSN602
is an oral dual serotonin a…

Reductil Slimming Pills for Obesity Treatment

Thursday, December 4th, 2008

Reductil slimming pills for obesity treatment

Reductil is a prescription medicine for weight loss or obesity treatment. Reductil works by affecting the centres in the brain that are respons…

Anti-Obesity Drugs: A short profile

Monday, December 1st, 2008

In the following article we bring you a profile of major anti-obesity drugs already on the market. This goes as follows:
Xenical
Approved by the U.S. FDA in 1999, Xenical (orlistat) is a lipase in…